# Jaguar Health (JAGX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/JAGX
## Company Profile
- Ticker: JAGX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 4.53 USD
- Market cap: 2116686.3200000003 USD
- Last updated: 2026-10-08
## Business Overview
Jaguar Health is a biopharmaceutical company focused on gastrointestinal and rare-disease therapies, with Mytesi as a key commercial asset. Its story combines niche commercialization with a pipeline aimed at high-unmet-need GI indications.
## Why The Stock Is Moving

As of Oct 8, 2026, JAGX closed down 9.40% at $4.53. No new same-company headline was identified in the current news window.

## Geographic Base

Jaguar Health is headquartered in the United States and listed on NASDAQ. It sits in specialty biopharma with a GI and rare-disease profile.

## Business Model

The business depends on product sales, label or indication expansion, and the ability to keep a narrow franchise financed. Investors usually watch commercial traction, regulatory progress, and pipeline updates.

## Landscape Position

Jaguar occupies a niche GI-specialty position within biotech. Its stock tends to move on commercial execution and the market's view of whether the portfolio can expand beyond a single product.

## Future Catalysts

- The next few months for Jaguar Health are centered on its latest development priorities. The latest company update points to commercial rights for Mytesi ® and Canalevia ® -CA1 Company continues its focus on crofelemer development efforts for rare-disease intestinal failure indications. If that progress holds, the program should stay on the radar through the rest of the quarter. The partnership angle also matters here, especially around Q4 2025, buoyed by license of U.S.

## Recent News
- 2026-10-06 13:00 EST — [Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi](https://biopharmsignal.com/news/JAGX/napo-pharmaceuticals-a-jaguar-health-family-company-sponsoring-intestinal-failur-a2745f90) — Source: Jaguar Health
- 2026-10-03 00:35 EST — [Jaguar Health Announces a Special Stock Dividend](https://biopharmsignal.com/news/JAGX/jaguar-health-announces-a-special-stock-dividend-202da3df) — Source: Jaguar Health
- 2026-09-29 08:30 EST — [Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting](https://biopharmsignal.com/news/JAGX/preliminary-results-of-open-label-study-in-adult-short-bowel-syndrome-patients-w-9fc78487) — Source: Jaguar Health
- 2026-09-22 13:05 EST — [Jaguar Health Receives Fee Waivers from FDA](https://biopharmsignal.com/news/JAGX/jaguar-health-receives-fee-waivers-from-fda-90e92ac7) — Source: Jaguar Health
- 2026-09-15 13:00 EST — [Jaguar Health, Inc. Announces Reverse Stock Split](https://biopharmsignal.com/news/JAGX/jaguar-health-inc-announces-reverse-stock-split-bad50836) — Source: Jaguar Health